Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking MS Therapeutics: From Disease Pathogenesis Mechanisms to AI-Driven Drug Discovery.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology·2026
Same author

Different behavior of NK cells isolated from healthy women and women with recurrent spontaneous abortion after treatment with human amniotic epithelial cells.

Journal of leukocyte biology·2025
Same author

Integrated bioprocessing and genetic strategies to enhance soluble expression of anti-HER2 immunotoxin in E. Coli.

AMB Express·2024
Same author

Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34<sup>+</sup> cells and PD-L1 CAR-modified UCB-CD34<sup>+</sup>-derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells.

Stem cell research & therapy·2024
Same author

Resistance exercise training augments the immunomodulatory adaptations to aerobic high-intensity interval training.

European journal of sport science·2023
Same author

Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy.

Biotechnology letters·2023

Related Experiment Video

Updated: May 13, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review.

Maryam Abbaspour1, Nafiseh Esmaeil2, Vajihe Akbari1

  • 1Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.

Breast Cancer (Dove Medical Press)
|May 12, 2026
PubMed
Summary

Immunotherapy, including immune checkpoint inhibitors (ICIs), shows promise for breast cancer (BC). Combining ICIs with other treatments may improve outcomes for various BC subtypes.

Keywords:
CAR NK cellsCAR T cellsbreast cancercheckpoint inhibitorsexosomesimmunotherapyoncolytic viruses

More Related Videos

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

Related Experiment Videos

Last Updated: May 13, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Breast cancer (BC) remains a significant cause of cancer mortality.
  • Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has shown efficacy in certain breast cancer subtypes, such as triple-negative breast cancer (TNBC).
  • Novel therapeutic strategies are crucial to improve outcomes for all breast cancer patients.

Purpose of the Study:

  • To review recent advancements in breast cancer immunotherapy.
  • To synthesize combination strategies for immunotherapy based on their mechanisms of action.
  • To provide a framework for biomarker-driven patient stratification and evaluate emerging therapeutic platforms.

Main Methods:

  • Narrative review of recent progress in breast cancer immunotherapy.
  • Synthesis of combination strategies into three mechanistic categories: tumor microenvironment remodeling, effector cell enhancement, and immune checkpoint modulation.
  • Evaluation of clinical maturity of emerging immunotherapy platforms.

Main Results:

  • Immune checkpoint inhibitors (ICIs) like pembrolizumab and atezolizumab are effective in triple-negative breast cancer (TNBC).
  • Combination strategies involving ICIs with chemotherapy, PARP inhibitors, oncolytic viruses, CAR-T cells, CAR-NK cells, and exosomes show potential for improving antitumor immune responses.
  • Emerging platforms and combination strategies offer new avenues for breast cancer treatment.

Conclusions:

  • Combination immunotherapies hold significant promise for improving breast cancer treatment outcomes.
  • Biomarker-driven patient stratification is essential for optimizing immunotherapy efficacy.
  • Further research and clinical trials are necessary to expand the application of these strategies across diverse breast cancer subtypes.